PHVS
Pharvaris N.V.
NASDAQ · Healthcare · Biotechnology · NL
$35.25
−1.15%Aug 12, 2026, 10:50 UTC
Pharvaris announced its financial results for the second quarter ending June 30, 2026, and provided a business update.
Source:Jul 6, 2026, 10:50 UTC
The U.S. FDA accepted Pharvaris's New Drug Application for deucrictibant IR for on-demand treatment of hereditary angioedema attacks.